• Fetck KC Callout
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 Insights™
dvm360 LIVE!™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Targeted injectable therapy for canine elbow osteoarthritis

June 28, 2022
Bob Alaburda, Senior Editor

Conferences | <b>Directions in Veterinary Medicine</b>

Industry-leading lecturers shared an emerging approach for multimodal osteoarthritis treatment

Osteoarthritis (OA) is a common diagnosis that can be severely debilitating for a pet’s mobility and quality of life. Managing this progressive and degenerative disease process has evolved over the years as research reveals new therapies as part of a multimodal approach. Two sessions, both sponsored by Synovetin OA, at the Directions in Veterinary Medicine conference in Indianapolis, Indiana, addressed osteoarthritis management, and highlighted modalities the speakers have brought into their own practices.

Radiosynoviorthesis: targeted injectable therapy for elbow OA

Matt Brunke, DVM, DACVSMR, CCRP, CVPP, CVA, and Kirsty Oliver, VN, DAVN (surgical), RVT, CCRP, CVPP, VTS (rehab), delivered the joint session “Injectable therapy for canine elbow osteoarthritis.” Brunke focused a portion of his talk on a technique called radiosynoviorthesis (Synovetin OA) as novel therapy approved for elbow OA management in canines. This therapy is an injection of radioactive Tin-117m that decreases macrophages and subsequently decreases synovitis, which is associated with the pain and inflammation at the heart of OA.1 Brunke addressed the concept of targeted therapy in a previously recorded episode of dvm360® Live™, in which he said: “If you only have one arthritic joint, why are we giving systemic meds? While [they are] safe and efficacious, there's a chance that they could have issues, and if your only issue is in 1 elbow, then why not approach that 1 elbow, right?2”

How does it work?

Although some treatments tend to treat OA by reducing inflammation or targeting the pain receptors, the aim of radiosynoviorthesis is to address the underlying disease state. Inside the joint affected by OA, a vicious cycle of inflammation causes the synovial membrane to swell and the cartilage to deteriorate, said Brunke. He explained radiosynoviorthesis treatment targets the macrophages and synovia sites that are being overproduced by the body and driving the inflammation and pain.1

Radiosynoviorthesis employs microparticles of the novel radionuclide Tin-117m, which are are suspended in a colloid and injected into the joint. The Tin-117m microparticles stay in the joint and emit low energy conversion electrons with 0.3-mm range of activity. This provides targeted, nonsystemic therapy without clinically significant local or systemic adverse effects, according to the manufacturer.3 Inflammatory macrophages and synovia sites selectively engulf the microparticles and are deactivated by the conversion electron energy. The microparticles remain active and are engulfed again by nearby synovia sites and macrophages for sustained action against inflammation. The microparticles decay to harmless inert tin, with clinical effects lasting up to a year with a single injection, says the manufacturer.3

Brunke and Oliver said this treatment is a valuable addition to their multimodal approach to OA. “The treatment for osteoarthritis needs to be multimodal,” said Oliver, while presenting her session “The What and How-tos of Physical Rehabilitation.” She continued,“We are past the days when… we just give some NSAIDs and tell them to take a rest for 10 to 14 days. We're better than that; we can do better than that.4”

Results in practice

Oliver said that she and Brunke have so far used this technique on 80 patients for a total of 137 joints, mostly dog elbows, in their practice and have been seeing improvements to mobility and pain that last upward of 12 months.4 “Hands down on efficacy, this has been my game changer,” said Brunke. “Instead of gaining like 5 or 10 degrees of range of motion, which is clinically relevant, we’re gaining 20 to 30 degrees of range of motion within a month. Our lameness scores are dropping from 3 to 1 within 2 months, and that has been beneficial.1”

Reference

  1. Brunke M, Oliver K. Injectable therapy for canine elbow osteoarthritis. Presented at: Directions in Veterinary Medicine; June 24-25, 2022; Indianapolis, Indiana.
  2. Targeted therapy for canine osteoarthritis. dvm360. June 15, 2022. Accessed June 22, 2022. https://www.dvm360.com/view/targeted-therapy-for-canine-osteoarthritis
  3. Donecker J, Stevenson NR. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation. 2020. Accessed June 27, 2022. https://www.synovetin.com/sites/default/files/2021-07/EXN-SYN-024%20RSO%20Tin117-m%20Tech%20Bulletin_MECH3_READER.pdf
  4. Oliver K. Introduction to rehabilitation: the what and how-tos of physical rehabilitation. Presented at: Directions in Veterinary Medicine; June 24-25, 2022; Indianapolis, Indiana.

Related Content:

Directions in Veterinary MedicinePain ManagementMedicalClinicalAssociatesTechniciansConference
Are you ready for the Fetch dvm360® Kansas City Block Party?
Are you ready for the Fetch dvm360® Kansas City Block Party?
Dr Mike Nolan receives 2022 AVMF/EveryCat Health Foundation Research Award
Dr Mike Nolan receives 2022 AVMF/EveryCat Health Foundation Research Award
Acupuncture therapy in pets
Acupuncture therapy in pets

Latest News

Are you ready for the Fetch dvm360® Kansas City Block Party?

Mini donkey successfully receives pacemaker to manage fatal heart condition

News wrap-up: This week’s headlines, plus Cincinnati Zoo welcomes baby hippo

Dr Mike Nolan receives 2022 AVMF/EveryCat Health Foundation Research Award

View More Latest News